<DOC>
	<DOCNO>NCT02749890</DOCNO>
	<brief_summary>Primary Objective : To compare LixiLan lixisenatide glycated hemoglobin ( HbA1c ) change baseline Week 26 patient type 2 diabetes mellitus . Secondary Objective : To compare overall efficacy safety LixiLan lixisenatide ( without OADs ) 52 week treatment period patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Efficacy Safety Insulin Glargine/Lixisenatide Fixed Ratio Combination ( LixiLan ) Lixisenatide Top Oral Anti-diabetic Drugs ( OADs ) With Type 2 Diabetes Japan</brief_title>
	<detailed_description>Approximately 55 week : up-to 2-week screening period , 26-week randomized open-label treatment period , 26-week safety extension treatment period 3-day post-treatment safety follow period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Inclusion criterion : Patient type 2 diabetes mellitus ( T2DM ) diagnose least 1 year screen visit , receive 1 2 OADs biguanide , thiazolidinedione , alphaglucosidaseinhibitor , sodium glucose cotransporter 2 inhibitor ; sulfonylurea , rapidacting insulin secretagogue , dipeptidylpeptidase4 inhibitor . Signed write informed consent . Exclusion criterion : At screen visit : age &lt; 20 year . At screen visit : HbA1c &lt; 7.5 % &gt; 10 % . At screen visit : fasting plasma glucose ( FPG ) &gt; 250 mg/dL ( 13.8 mmol/L ) . Pregnancy lactation , woman childbearing potential effective contraceptive method . Use oral injectable glucoselowering agent state inclusion criterion 3 month screen visit . Previous treatment insulin ( except shortterm treatment due intercurrent illness include gestational diabetes discretion trial physician ) . Laboratory finding screen visit , include : Amylase and/or lipase &gt; 3 time upper limit normal laboratory range ( ULN ) , Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 ULN , Calcitonin â‰¥20 pg/mL ( 5.9 pmol/L ) , Positive serum pregnancy test . Contraindication use lixisenatide accord local labeling . History hypersensitivity glucagonlike peptide1 receptor agonist ( GLP1RA ) metacresol . Contraindication use insulin glargine accord local labeling . History hypersensitivity insulin glargine excipients . Patient severe renal function impairment estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m^2 endstage renal disease patient treat metformin . Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC ( eg , multiple endocrine neoplasia syndrome ) . History pancreatitis ( unless pancreatitis relate gallstone cholecystectomy perform ) , pancreatitis previous treatment incretin therapy , chronic pancreatitis , pancreatectomy , stomach/gastric surgery . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>